Kids who play with letter and number puzzles for fun grow up to start venture capital firms with alphanumeric names. At least, that was the case for Adele Oliva, partner of 1315 Capital LLC, which just closed a $200 million inaugural fund. The Philadelphia-based firm invests in commercial-stage companies in the medical technology, specialty pharmaceutical and health care services sectors.

Kids who play with letter and number puzzles for fun grow up to start venture capital firms with alphanumeric names. At least, that was the case for Adele Oliva, partner of 1315 Capital LLC, which just closed a $200 million inaugural fund. The Philadelphia-based firm invests in commercial-stage companies in the medical technology, specialty pharmaceutical and health care services sectors.

The urge to go on biggering and biggering and biggering has taken over the med-tech world. Barely a year after Zimmer and Biomet completed a $14 billion merger to become the second largest orthopedic device maker, the company now plans to spend another $1 billion to buy LDR and grow its spine business. Not too long ago a deal this size would have been considered a blockbuster for the medical device industry. But after two years of mega-mergers like Zimmer-Biomet, Medtronic-Covidien ($42.9 billion) and the still-pending $25 billion merger of Abbott and St. Jude Medical, this latest acquisition pales by...

Shares of Boston Scientific Corp. (NYSE: BSX) reached a 10-year high Thursday after the company reported a global restructuring program to cut its annual expenses anywhere from $115 million to $150 million by the end of 2020. The stock climbed 2.28 percent (52 cents) to close at $23.32 Thursday, the highest it has been since Feb 1, 2006 when the stock closed at $24.42.